{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:56:43Z","timestamp":1790035003363,"version":"4.0.1"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":221,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Skin Cancer"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cemiplimab has been licensed for use in the United Kingdom as the sole immunotherapy agent for first\u2010line use in advanced cutaneous squamous cell carcinoma (a\u2010cSCC). Given that previous clinical trials leading to the approval of cemiplimab had relatively small patient cohorts with relatively short follow\u2010up periods, with a large proportion of patients who had received prior systemic treatment, this retrospective real\u2010world study sought to add further insight into survival and toxicity in patients who exclusively had received first\u2010line use of cemiplimab, as well as comparing response rates (RRs) based on primary site location.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study identified patients diagnosed with a\u2010cSCC between 01\/08\/2019 and 31\/03\/2024 who received cemiplimab as first\u2010line treatment at our institution. Data to enable response assessment and toxicity were collected and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      50 patients were identified with a mean age of 75\u2009years (range: 44\u201394). 78% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200939) of the patients\u2019 primary lesion originated from the head and neck (H&amp;N) region, whilst the remaining 22% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200911) had a primary lesion from other areas. No patients had received prior systemic treatment for a\u2010cSCC. Overall, the disease control rate (DCR) was 74%, and the RR was 55.8% with complete response in 35% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200915), partial response in 21% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099), and stable disease in 19% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098). In patients with H&amp;N primary site of disease, RR was 58.9% versus 27.2% in patients with non\u2010H&amp;N primary site of disease, with a\n                      <jats:italic>p<\/jats:italic>\n                      value of 0.027. The overall mean PFS for the study population was 27.3\u2009months (95% CI: 21.2\u201333.5\u2009months), with the median PFS not reached for the study duration. The median PFS for patients with H&amp;N primary site of disease was not reached as compared to the median PFS of 4\u2009months (95% CI: 2.2\u20135.7\u2009months) for patients with non\u2010H&amp;N primary site of disease, with a\n                      <jats:italic>p<\/jats:italic>\n                      value of 0.049. The median OS for the study population was 34\u2009months (95% CI: 15.4\u201352.5\u2009months). Grade 3 toxicities were reported in 22% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200911) with no Grade 4 toxicites.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The use of cemiplimab as first\u2010line treatment in a\u2010cSCC demonstrates high efficacy and low rates of serious toxicity, which is especially reassuring in a patient cohort comprising of more elderly patients. The high complete RR seen in our patient cohort may reflect the exclusive first\u2010line use of cemiplimab in our study, as per now established real\u2010world practice in a\u2010cSCC. Higher RRs and PFS are seen in patients with head\/neck primary site of disease vs. non head\/neck primary site, which should be evaluated further in future clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1155\/jskc\/8993856","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:16:37Z","timestamp":1786356997000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real\u2010World Response of Cemiplimab Immunotherapy for Treating Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma in a Tertiary UK Oncology Centre"],"prefix":"10.1155","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9583-5330","authenticated-orcid":false,"given":"Sumbal","family":"Umar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9029-5234","authenticated-orcid":false,"given":"Zarmeen","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-294X","authenticated-orcid":false,"given":"Micheal","family":"O\u2019Cathail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-3348","authenticated-orcid":false,"given":"M. Ananth","family":"Sivanandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"e_1_2_9_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2020.10.013"},{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra2206348"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/life11040326"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.01.008"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.959289"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s445910"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1805131"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2209813"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.10.001"},{"key":"e_1_2_9_10_2","volume-title":"Cemiplimab for Treating Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma. Technology Appraisal Guidance TA802","author":"National Institute for Health and Care Excellence","year":"2022"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcskn.2023.100007"},{"key":"e_1_2_9_12_2","volume-title":"Policy on Ethics Review for Quality Improvement Reports","author":"BMJ Quality & Safety"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1408667"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.09.018"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-71788-z"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_438654"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112996"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-023-00256-1"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.08.018"}],"container-title":["Journal of Skin Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/jskc\/8993856","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/jskc\/8993856","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/jskc\/8993856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:16:39Z","timestamp":1786356999000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/jskc\/8993856"}},"subtitle":[],"editor":[{"given":"Richa","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1155\/jskc\/8993856"],"URL":"https:\/\/doi.org\/10.1155\/jskc\/8993856","archive":["Portico"],"relation":{},"ISSN":["2090-2905","2090-2913"],"issn-type":[{"value":"2090-2905","type":"print"},{"value":"2090-2913","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-08-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"8993856"}}